
Orgenesis ORGS
Annual report 2024
added 03-26-2026
Orgenesis DSO Ratio 2011-2026 | ORGS
Annual DSO Ratio Orgenesis
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 22.6 | 12.5 K | 200 | 14 | 155 | 117 | 219 | 80 | 122 | 321 | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 12.5 K | 14 | 1.37 K |
Quarterly DSO Ratio Orgenesis
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 52.7 | 90 | 108 | - | 31.9 | 8.62 K | 18.5 K | - | 243 | 227 | 204 | - | 174 | 124 | 58.8 | - | 163 | 161 | 119 | - | 136 | 148 | 199 | - | 10.1 | 22.8 | 32.2 | - | 24.6 | 27.4 | 17 | - | 60.6 | 99.1 | 72.1 | - | 114 | 131 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 18.5 K | 10.1 | 1.03 K |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
I-Mab
IMAB
|
271 | - | - | $ 866 M | ||
|
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | ||
|
Aptorum Group Limited
APM
|
20.6 | $ 0.89 | - | $ 6.54 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
37.5 | $ 22.2 | - | $ 3.68 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | ||
|
Edesa Biotech
EDSA
|
97.1 | $ 15.9 | - | $ 50.8 M | ||
|
Evogene Ltd.
EVGN
|
30 | $ 0.76 | - | $ 27.9 M | ||
|
Exelixis
EXEL
|
43.4 | $ 44.69 | - | $ 12.1 B | ||
|
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | ||
|
Galapagos NV
GLPG
|
56.5 | $ 27.86 | - | $ 2.69 B | ||
|
Harmony Biosciences Holdings
HRMY
|
37.8 | $ 31.05 | - | $ 1.79 B | ||
|
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | ||
|
ImmuCell Corporation
ICCC
|
47.5 | $ 8.44 | - | $ 76.2 M | ||
|
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | ||
|
Immuron Limited
IMRN
|
148 | $ 0.81 | 0.3 % | $ 9.47 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M | ||
|
Incyte Corporation
INCY
|
66.6 | $ 99.1 | - | $ 19.3 B | ||
|
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | ||
|
InMed Pharmaceuticals
INM
|
3.83 | $ 0.7 | - | $ 1.71 M | ||
|
INmune Bio
INMB
|
19.9 K | $ 1.33 | - | $ 32.9 M | ||
|
Innoviva
INVA
|
24.6 | $ 23.05 | - | $ 1.55 B | ||
|
Jaguar Health
JAGX
|
48.3 | $ 7.88 | - | $ 18.4 M | ||
|
KalVista Pharmaceuticals
KALV
|
9.64 | $ 26.67 | - | $ 1.44 B | ||
|
Kamada Ltd.
KMDA
|
103 | $ 8.11 | - | $ 260 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 2.98 | - | $ 4.91 M | ||
|
Krystal Biotech
KRYS
|
109 | $ 259.95 | - | $ 7.52 B | ||
|
Kazia Therapeutics Limited
KZIA
|
28.7 | $ 12.42 | - | $ 1.65 B | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
77.8 | $ 224.86 | - | $ 4.11 B | ||
|
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M | ||
|
Liquidia Corporation
LQDA
|
65.5 | $ 38.15 | - | $ 3.28 B | ||
|
Aquestive Therapeutics
AQST
|
103 | $ 4.05 | - | $ 433 M | ||
|
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M |